In light of the potential benefits of BDNF AntagoNAT therapy in PD and the limitations for its delivery, we hypothesized that our heterotopic mucosal grafting approach could be utilized as a novel method for the direct CNS delivery of AntagoNAT’s. Here, BDNF is linked to Parkinson disease.